Guinea pig complement potently measures vibriocidal activity of human antibodies in response to cholera vaccines
The vibriocidal assay using guinea pig complement is widely used for the evaluation of immune responses to cholera vaccines in human clinical trials. However, it is unclear why guinea pig complement has been used over human complement in the measurement of vibriocidal activity of human sera and there have not been comparison studies for the use of guinea pig complement over those from other species. Therefore, we comparatively investigated the effects of complements derived from human, guinea pig, rabbit, and sheep on vibriocidal activity. Complements from guinea pig, rabbit, and human showed concentration-dependent vibriocidal activity in the presence of quality control serum antibodies. Of these complements, guinea pig complement was the most sensitive and effective over a wide concentration range. When the vibriocidal activity of complements was measured in the absence of serum antibodies, human, sheep, and guinea pig complements showed vibriocidal activity up to 40-fold, 20-fold, and 1-fold dilution, respectively. For human pre- and post-vaccination sera, the most potent vibriocidal activity was observed when guinea pig complement was used. In addition, the highest fold-increases between pre- and post- vaccinated sera were obtained with guinea pig complement. Furthermore, human complement contained a higher amount of V. cholerae- and its lipopolysaccharide-specific antibodies than guinea pig complement. Collectively, these results suggest that guinea pig complements are suitable for vibriocidal assays due to their high sensitivity and effectiveness to human sera.
KeywordsVibrio cholerae vibriocidal assay guinea pig complement cholera vaccine
Unable to display preview. Download preview PDF.
- Anh, D.D., Canh, D.G., Lopez, A.L., Thiem, V.D., Long, P.T., Son, N.H., Deen, J., von Seidlein, L., Carbis, R., Han, S.H., et al. 2007. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25, 1149–1155.CrossRefPubMedGoogle Scholar
- Aung, K.M., Sjostrom, A.E., von Pawel-Rammingen, U., Riesbeck, K., Uhlin, B.E., and Wai, S.N. 2016. Naturally occurring IgG antibodies provide innate protection against Vibrio cholerae bacteremia by recognition of the outer membrane protein U. J. Innate Immun. 8, 269–283.CrossRefPubMedGoogle Scholar
- Boutonnier, A., Dassy, B., Dumenil, R., Guenole, A., Ratsitorahina, M., Migliani, R., and Fournier, J.M. 2003. A simple and convenient microtiter plate assay for the detection of bactericidal antibodies to Vibrio cholerae O1 and Vibrio cholerae O139. J. Microbiol. Methods 55, 745–753.CrossRefPubMedGoogle Scholar
- Chen, W.H., Greenberg, R.N., Pasetti, M.F., Livio, S., Lock, M., Gurwith, M., and Levine, M.M. 2014. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks. Clin. Vaccine Immunol. 21, 66–73.CrossRefPubMedPubMedCentralGoogle Scholar
- Finkelstein, R.A. 1962. Vibriocidal Antibody Inhibition (VAI) analysis: A technique for the identification of the predominant vibriocidal antibodies in serum and for the detection and identification of Vibrio cholerae antigens. J. Immunol. 89, 264–271.Google Scholar
- Kanungo, S., Lopez, A.L., Ali, M., Manna, B., Kim, D.R., Mahapatra, T., Holmgren, J., Dhingra, M.S., Weirzba, T.F., Nair, G.B., et al. 2014. Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India. PLoS One 9, e96499.CrossRefGoogle Scholar
- Kanungo, S., Paisley, A., Lopez, A.L., Bhattacharya, M., Manna, B., Kim, D.R., Han, S.H., Attridge, S., Carbis, R., Rao, R., et al. 2009}. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebocontrolled trial. Vaccine 27, 6887–6893.CrossRefPubMedGoogle Scholar
- Mahalanabis, D., Lopez, A.L., Sur, D., Deen, J., Manna, B., Kanungo, S., von Seidlein, L., Carbis, R., Han, S.H., Shin, S.H., et al. 2008. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One 3, e2323.CrossRefGoogle Scholar
- Nguyen, V.D., Sreenivasan, N., Lam, E., Ayers, T., Kargbo, D., Dafae, F., Jambai, A., Alemu, W., Kamara, A., Islam, M.S., et al. 2014. Cholera epidemic associated with consumption of unsafe drinking water and street-vended water-Eastern Freetown, Sierra Leone, 2012. Am. J. Trop. Med. Hyg. 90, 518–523.CrossRefPubMedPubMedCentralGoogle Scholar